Frontiers in Medicine · 2021 · 11 citations · 32 references
PharmacyNephrologyPharmacotherapyClinical NutritionRenal PathophysiologyRenal PharmacotherapyBlood Pressure ManagementChronic Kidney DiseaseHypertension ManagementRenal DiseaseRenal ImpairmentArterial Blood Pressure ControlArterial Blood Pressure MeasurementBicarbonate LoadingBlood PressureCkd ProgressionSodium Bicarbonate SupplementationSodium Bicarbonate TherapySodium Supplementation
Background: Sodium bicarbonate supplementation is a mainstay in the treatment of metabolic acidosis in patients with chronic kidney disease (CKD). Recent studies showed reduction of progression of CKD and reduced all-cause mortality. However, additional sodium loading could worsen arterial hypertension, a well-known contributor to progression of CKD. This patient-relevant and economically negative side effect is under-studied in prospective studies up until now. Objective: The aim of this study was to analyze the effect of sodium bicarbonate treatment on arterial blood pressure at baseline and after 8 weeks. Methods: The SoBic study is an ongoing randomized controlled trial, in which patients with CKD receive either a high dose of oral sodium bicarbonate or a rescue treatment, if necessary. We used standardized office blood pressure and 24-hour ambulatory blood pressure monitoring (24h-ABPM). Regression models were adjusted for estimated glomerular filtration rate and change of antihypertensives. Results: 47 subjects were enrolled and the mean age was 57 (±14.6) years and 18 (38%) were female. In 43 randomized subjects with sufficiently performed 24h-ABPM neither systolic 24h-ABPM (2.522; 95%CI: −2.364, 7.408; mmHg) nor diastolic 24h-ABPM (0.868; 95%CI: −2.411, 4.147; mmHg) was affected by study group allocation. When looking at the effect of individual sodium bicarbonate dose on 24h-ABPM, the fully adjusted model suggested an increase of 0.047 (95%CI: −0.026, 0.119) mmHg by each mg/kg per day increase of sodium bicarbonate dose. Conclusion: Sodium bicarbonate supplementation over 8 weeks did not significantly increase blood pressure measured by 24h-ABPM in CKD patients. Trial Registration: EUDRACT Number: 2012-001824-36; 12/07/2012 ( https://www.clinicaltrialsregister.eu ).
32
Nimrit Goraya, Chan‐Hee Jo, Donald E. Wesson · Clinical Journal of the American Society of Nephrology · 2013 · 404 citations · Full text
Medicine, Nephrology, Nutrition +17
Nimrit Goraya, Chan‐Hee Jo, Donald E. Wesson · Kidney International · 2014 · 392 citations
Medicine, Biochemistry, Nephrology +11
Nimrit Goraya, Chan‐Hee Jo, Donald E. Wesson · Kidney International · 2011 · 319 citations · Full text